List of Evoclin drug patents
Evoclin is owned by Mylan.
Evoclin contains Clindamycin Phosphate.
Evoclin has a total of 2 drug patents out of which 0 drug patents have expired.
Evoclin was authorised for market use on 22 October, 2004.
Evoclin is available in aerosol, foam;topical dosage forms.
Evoclin can be used as treatment of acne vulgaris.
The generics of Evoclin are possible to be released after 03 February, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7374747 | MYLAN | Pharmaceutical foam |
Jan, 2024
(7 months from now) | |
| US7141237 | MYLAN | Pharmaceutical foam |
Feb, 2024
(8 months from now) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 22 October, 2004
Treatment: Treatment of acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
EVOCLIN family patents
8
United States
3
Australia
2
Spain
2
Israel
2
Taiwan
2
Argentina
2
EA
2
Japan
2
European Union
1
New Zealand
1
Yugoslavia
1
Mexico
1
Brazil
1
Canada
1
Norway
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic